arrow-down arrow-left arrow-right arrow-up cross download facebook link-external linkedin magazine mail search twitter xing


Img 4552 1 Sw

Biological wound care with the Aurase® enzyme

The combination of natural biodiversity and biotechnology opens up new prospects in wound treatment. This benefits patients, nursing staff and the health system in equal measure. Speciality enzymes point the way.

There is a growing number of patients with chronic wounds in Europe and other parts of the world. The number of cases in Germany alone is estimated at three million, but there is bound to be a large number of unreported cases. Since this mainly concerns elderly people, demographic change is pushing up patient figures. Other factors include diet-related conditions such as obesity, diabetes or malnutrition.

BRAIN’s researchers have developed a new treatment to improve the situation of wound patients. The active principle is an enzyme with the product name Aurase®, which is modelled on the maggots of the common green bottle fly (Lucilia sericata). It has been known for centuries that open wounds infected with these maggots heal better. BRAIN has translated this gift from nature’s treasure trove into new wound care products.

The starting point was the identification of an enzyme that promotes wound cleaning in maggot therapies. The high-purity Aurase® enzyme is produced by means of biotechnological processes. The product name was based on the Latin for gold (aurum) and refers to the German name of the fly (literally “golden fly”) that served as the natural model.

BRAIN has steadily extended its patent coverage for the commercial use of Aurase® continuously. Currently specific applications and various marketing options are being explored. The objective is to create a range of Aurase® products based on proven processes for wound treatment.

Aurase® …

… is a new enzymatic active ingredient developed by BRAIN for the biological treatment of open wounds.

… illustrates the enormous and still largely untapped potential of biodiversity, here based on the common “golden fly” as a natural model. BRAIN’s BioArchive contains a sliver of this biodiversity.

… is a new enzyme for which BRAIN has already received patent coverage in some 20 countries throughout Europe, Asia, North America, Oceania and Africa, tapping into fast growing market for the treatment of chronic wounds.

… is a gentle option for the growing number of chronic wound patients, and an effective addition to other existing and sometimes painful and unpleasant procedures such as surgical debridement or maggot therapy.

Scroll to top